MXPA03010634A - Uso de inhibidores de proteasoma para tratar trastornos del ojo seco. - Google Patents

Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.

Info

Publication number
MXPA03010634A
MXPA03010634A MXPA03010634A MXPA03010634A MXPA03010634A MX PA03010634 A MXPA03010634 A MX PA03010634A MX PA03010634 A MXPA03010634 A MX PA03010634A MX PA03010634 A MXPA03010634 A MX PA03010634A MX PA03010634 A MXPA03010634 A MX PA03010634A
Authority
MX
Mexico
Prior art keywords
dry eye
proteasome inhibitors
eye disorders
treat dry
disorders
Prior art date
Application number
MXPA03010634A
Other languages
English (en)
Inventor
G Klimko Peter
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA03010634A publication Critical patent/MXPA03010634A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Los inhibidores de proteasoma son utiles para el tratamiento de trastornos del ojo seco y otros trastornos que requieren humedecer el ojo.
MXPA03010634A 2001-05-21 2002-05-17 Uso de inhibidores de proteasoma para tratar trastornos del ojo seco. MXPA03010634A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
PCT/US2002/015775 WO2002094311A1 (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Publications (1)

Publication Number Publication Date
MXPA03010634A true MXPA03010634A (es) 2004-03-09

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010634A MXPA03010634A (es) 2001-05-21 2002-05-17 Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.

Country Status (17)

Country Link
US (1) US6740674B2 (es)
EP (1) EP1392355B1 (es)
JP (1) JP2004530699A (es)
CN (1) CN1509183A (es)
AT (1) ATE353667T1 (es)
AU (1) AU2002308760B2 (es)
BR (1) BR0209883A (es)
CA (1) CA2447909C (es)
CY (1) CY1107531T1 (es)
DE (1) DE60218153T2 (es)
DK (1) DK1392355T3 (es)
ES (1) ES2278049T3 (es)
MX (1) MXPA03010634A (es)
PL (1) PL367287A1 (es)
PT (1) PT1392355E (es)
WO (1) WO2002094311A1 (es)
ZA (1) ZA200308768B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
KR20160086980A (ko) * 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
EP0643581B1 (en) 1992-04-21 1999-10-20 The Schepens Eye Research Institute, Inc. Ocular androgen therapy in sjögren's syndrome
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
NZ337364A (en) 1997-02-15 2001-06-29 Millennium Pharm Inc Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
CA2304622A1 (en) 1997-09-25 1999-04-01 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AU742237B2 (en) 1998-07-14 2001-12-20 Alcon Manufacturing Limited Use of 11-(3-dimenthylaminopropylidene)-6,11-dihydrodibenz (B,E)oxepin-2-acetic acid for the manufacture of medicament for treating non-allergic opthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
WO2000043000A1 (fr) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
AU4555800A (en) 1999-04-27 2000-11-10 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
PL367287A1 (en) 2005-02-21
ZA200308768B (en) 2005-01-26
US6740674B2 (en) 2004-05-25
WO2002094311A1 (en) 2002-11-28
US20030008910A1 (en) 2003-01-09
CN1509183A (zh) 2004-06-30
AU2002308760B2 (en) 2006-05-11
JP2004530699A (ja) 2004-10-07
DE60218153T2 (de) 2007-06-28
CA2447909A1 (en) 2002-11-28
ATE353667T1 (de) 2007-03-15
DE60218153D1 (de) 2007-03-29
PT1392355E (pt) 2007-03-30
EP1392355A1 (en) 2004-03-03
BR0209883A (pt) 2004-06-08
EP1392355B1 (en) 2007-02-14
DK1392355T3 (da) 2007-04-30
CY1107531T1 (el) 2013-03-13
ES2278049T3 (es) 2007-08-01
CA2447909C (en) 2011-04-05

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
ATE305307T1 (de) Reboxetin zur behandlung von migränekopfschmerzen
NZ335981A (en) Ketobenzamides as calpain inhibitors
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
HK1051499A1 (en) Method for treating ocular pain
PL350291A1 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ZA200609220B (en) Method of treating dry eye disorders and uveitis
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA03000313A (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea.
IL139144A0 (en) Mycobacterial inhibitors
PL367286A1 (en) Use of nfkb inhibitors to treat dry eye disorders
SG144942A1 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
MY140194A (en) Novel fusidic acid derivatives
AP2000001963A0 (en) Paroxetine ascorbate.
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration